// App-Quantinova.ai

7007 : Phase 1b/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive Patients Aged 65 Years with Acute Myelogenous Leukemia

Researchers

Presenter

  • Tara L. Lin

Principal Investigators

  • Stephen Anthony Strickland

  • Walter Fiedler

  • Roland B. Walter

  • Jing-Zhou Hou

  • Gail J. Roboz

  • Anoop Enjeti

  • Kaffa Mussumeh Fakhoui

  • David E Darden

  • Martin Dunbar

  • Ming Zhu

  • John W. Hayslip

  • Andrew H. Wei

Medical Centers

  • University of Kansas Medical Center, Kansas City, MO

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Hubertus Wald Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • University of Washington, Seattle, WA

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA

  • Weill Cornell Medical College, New York, NY

  • and School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia

  • AbbVie, Inc., North Chicago, IL

  • The Alfred Hospital and Monash University, Melbourne, Australia

Locations

  • United States

  • Germany

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Cytarabine liposomal

  • Venetoclax

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Expansion Study

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02287233

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved